Literature DB >> 19165808

The changing face of phase 1 cancer clinical trials: new challenges in study requirements.

Barbara S Craft1, Razelle Kurzrock, Xiudong Lei, Roy Herbst, Scott Lippman, Siqing Fu, Daniel D Karp.   

Abstract

Phase 1 studies in cancer have changed in recent years. Now, with the advent of new, less toxic, targeted agents, more patients may be candidates for new drug studies earlier in the course of their disease. It is to the advantage of the members of the oncology community to know more regarding the details and requirements for participation in early-phase clinical trials so they can advocate for their patients and help them decide when such trials may be an appropriate choice. To examine the work intensity of early phase cancer clinical trials, the authors of this report compared the study requirements of phase 1 and 2 protocols. Five parameters were studied as a surrogate of study complexity-the number of physical examinations, vital sign determinations, electrocardiograms (ECGs), nonpharmacokinetic laboratory tests, and pharmacokinetic (PK) sampling-in the first 4 weeks of protocol in 90 studies (49 phase 1 studies and 41 phase 2 studies). From July 2004 through March 2007, there were 49 phase 1 trials in the phase 1 Program, 9 phase 2 studies that were conducted by physicians appointed in that program, and 32 phase 2 trials with accessible data in the Department of Thoracic/Head & Neck Medical Oncology. In the phase 1 trials versus the phase 2 trials, there were significantly more (P < .05) physical examinations (mean +/- standard error, 3.16 +/- 0.24 vs 2.22 +/- 0.13), vital sign determinations (5.63 +/- 0.61 vs 2.80 +/- 0.26), ECGs (4.36 +/- 1.16 vs 0.80 +/- 0.17), nonpharmacokinetic laboratory tests (18.08 +/- 1.31 vs 10.12 +/- 0.65), and PK sampling (15.14 +/- 1.79 vs 1.02 +/- 0.53). These values also differed significantly (P < .005 for each) when the median values were compared in nonparametric tests. Although both phase 1 and phase 2 trials had substantial study requirements, those for the phase 1 studies were significantly higher. The successful conduct of early-phase clinical trials requires significant research infrastructure.

Entities:  

Mesh:

Year:  2009        PMID: 19165808      PMCID: PMC2668727          DOI: 10.1002/cncr.24171

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  25 in total

1.  Improving protection for research subjects.

Authors:  Robert Steinbrook
Journal:  N Engl J Med       Date:  2002-05-02       Impact factor: 91.245

Review 2.  Novel endpoints and design of early clinical trials.

Authors:  W R Parulekar; E A Eisenhauer
Journal:  Ann Oncol       Date:  2002       Impact factor: 32.976

3.  Phase I clinical trial design in cancer drug development.

Authors:  E A Eisenhauer; P J O'Dwyer; M Christian; J S Humphrey
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

4.  The costs of conducting clinical research.

Authors:  Ezekiel J Emanuel; Lowell E Schnipper; Deborah Y Kamin; Jenifer Levinson; Allen S Lichter
Journal:  J Clin Oncol       Date:  2003-10-14       Impact factor: 44.544

5.  Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic agents.

Authors:  Edward L Korn
Journal:  J Natl Cancer Inst       Date:  2004-07-07       Impact factor: 13.506

6.  Measuring the incremental cost of clinical cancer research.

Authors:  D P Goldman; M L Schoenbaum; A L Potosky; J C Weeks; S H Berry; J J Escarce; B A Weidmer; M L Kilgore; N Wagle; J L Adams; R A Figlin; J H Lewis; J Cohen; R Kaplan; M McCabe
Journal:  J Clin Oncol       Date:  2001-01-01       Impact factor: 44.544

7.  Factors affecting workload of cancer clinical trials: results of a multicenter study of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  Kathyrn Roche; Nancy Paul; Bobbi Smuck; Marlo Whitehead; Benny Zee; Joseph Pater; Mary-Anne Hiatt; Hugh Walker
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

8.  Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern University clinical trials costs and charges project.

Authors:  C L Bennett; T J Stinson; V Vogel; L Robertson; D Leedy; P O'Brien; J Hobbs; T Sutton; J C Ruckdeschel; T N Chirikos; R S Weiner; M M Ramsey; M S Wicha
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

9.  Using patients as their own controls for cost evaluation of phase I clinical trials.

Authors:  Eric J Sherman; David M Rubin; Ennapadam Venkatraman; Gary K Schwartz; Vincent A Miller; Mark H Radzyner; Hirsch S Ruchlin; David Spriggs; David G Pfister
Journal:  J Clin Oncol       Date:  2004-04-01       Impact factor: 44.544

10.  Incremental treatment costs in national cancer institute-sponsored clinical trials.

Authors:  Dana P Goldman; Sandra H Berry; Mary S McCabe; Meredith L Kilgore; Arnold L Potosky; Michael L Schoenbaum; Matthias Schonlau; Jane C Weeks; Richard Kaplan; Jose J Escarce
Journal:  JAMA       Date:  2003-06-11       Impact factor: 56.272

View more
  8 in total

1.  Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs.

Authors:  A Naing; H Veasey-Rodrigues; D S Hong; S Fu; G S Falchook; J J Wheler; A M Tsimberidou; S Wen; S N Fessahaye; E C Golden; J Aaron; M S Ewer; R Kurzrock
Journal:  Ann Oncol       Date:  2012-06-27       Impact factor: 32.976

Review 2.  Compliance in early-phase cancer clinical trials research.

Authors:  Razelle Kurzrock; David J Stewart
Journal:  Oncologist       Date:  2013-03-01

3.  Evaluation of patient enrollment in oncology phase I clinical trials.

Authors:  Diane A J van der Biessen; Merlijn A Cranendonk; Gaia Schiavon; Bronno van der Holt; Erik A C Wiemer; Ferry A L M Eskens; Jaap Verweij; Maja J A de Jonge; Ron H J Mathijssen
Journal:  Oncologist       Date:  2013-02-21

4.  Increasing complexity in oncology phase I clinical trials.

Authors:  Laeeq Malik; David Lu
Journal:  Invest New Drugs       Date:  2018-11-16       Impact factor: 3.850

5.  Early-phase clinical trials in the community: results from the national cancer institute community cancer centers program early-phase working group baseline assessment.

Authors:  Howard A Zaren; Suresh Nair; Ronald S Go; Rebecca A Enos; Keith S Lanier; Michael A Thompson; Jinxiu Zhao; Deborah L Fleming; John C Leighton; Thomas E Gribbin; Donna M Bryant; Angela Carrigan; Jennifer C Corpening; Kimberly A Csapo; Eileen P Dimond; Christie Ellison; Maria M Gonzalez; Jodi L Harr; Kathy Wilkinson; Andrea M Denicoff
Journal:  J Oncol Pract       Date:  2013-03       Impact factor: 3.840

6.  Parental Experiences of Child Participation in a Phase I Pediatric Oncology Clinical Trial: "We Don't Have Time to Waste".

Authors:  Stacey Crane; Joan E Haase; Susan E Hickman
Journal:  Qual Health Res       Date:  2018-04-11

Review 7.  Parents' Insights into Pediatric Oncology Phase I Clinical Trials: Experiences from Their Child's Participation.

Authors:  Stacey Crane; James M Croop; Jill Lee; Jamie Walski; Joan Haase
Journal:  Semin Oncol Nurs       Date:  2021-06-18       Impact factor: 3.527

8.  The importance of greater speed in drug development for advanced malignancies.

Authors:  David J Stewart; Andrew A Stewart; Paul Wheatley-Price; Gerald Batist; Hagop M Kantarjian; Joan Schiller; Mark Clemons; John-Peter Bradford; Laurel Gillespie; Razelle Kurzrock
Journal:  Cancer Med       Date:  2018-03-30       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.